Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants

References

• Cortese S, Song M, Farhat LC, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the global burden of disease study. Mol Psychiatry. 2023 Sep 8;28(11):4823–4830. doi: 10.1038/s41380-023-02228-3
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association, American Psychiatric Association. DSM-5 task force. Diagnostic and statistical manual of mental disorders : dSM-5. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Wu SY, Gau SS. Correlates for academic performance and school functioning among youths with and without persistent attention-deficit/hyperactivity disorder. Res Dev Disabil. 2013 Jan;34(1):505–515. doi: 10.1016/j.ridd.2012.09.004
   PubMed Web of Science ®Google Scholar
• Efron D, Sciberras E, Anderson V, et al. Functional status in children with ADHD at age 6–8: a controlled community study. Pediatrics. 2014 Oct;134(4):e992–e1000. doi: 10.1542/peds.2014-1027
   PubMed Web of Science ®Google Scholar
• Eakin L, Minde K, Hechtman L, et al. The marital and family functioning of adults with ADHD and their spouses. J Atten Disord. 2004 Aug;8(1):1–10. doi: 10.1177/108705470400800101
   PubMedGoogle Scholar
• Harpin V, Mazzone L, Raynaud JP, et al. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016 Apr;20(4):295–305. doi: 10.1177/1087054713486516
   PubMed Web of Science ®Google Scholar
• Chronis-Tuscano A, Raggi VL, Clarke TL, et al. Associations between maternal attention-deficit/hyperactivity disorder symptoms and parenting. J Abnorm Child Psychol. 2008 Nov;36(8):1237–1250. doi: 10.1007/s10802-008-9246-4
   PubMed Web of Science ®Google Scholar
• Owens EB, Hinshaw SP. Adolescent mediators of unplanned pregnancy among women with and without childhood ADHD. J Clin Child Adolesc Psychol. 2020 Mar;49(2):229–238. doi: 10.1080/15374416.2018.1547970
   PubMed Web of Science ®Google Scholar
• Helgesson M, Rahman S, Bjorkenstam E, et al. Trajectories of labour market marginalisation among young adults with newly diagnosed attention-deficit/hyperactivity disorder (ADHD). Epidemiol Psychiatr Sci. 2021 Oct 22;30:e67. doi: 10.1017/S2045796021000536
   PubMed Web of Science ®Google Scholar
• Schiavone N, Virta M, Leppamaki S, et al. Mortality in individuals with childhood ADHD or subthreshold symptoms – a prospective perinatal risk cohort study over 40 years. BMC Psychiatry. 2022 May 9;22(1):325. doi: 10.1186/s12888-022-03967-3
   PubMed Web of Science ®Google Scholar
• Chang Z, Ghirardi L, Quinn PD, et al. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry. 2019 Sep 1;86(5):335–343. doi: 10.1016/j.biopsych.2019.04.009
   PubMed Web of Science ®Google Scholar
• Chorniy A, Kitashima L. Sex, drugs, and ADHD: the effects of ADHD pharmacological treatment on teens’ risky behaviors. Labour Econ. 2016;43:87–105. doi: 10.1016/j.labeco.2016.06.014
   Web of Science ®Google Scholar
• Coghill DR, Banaschewski T, Soutullo C, et al. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017 Nov;26(11):1283–1307. doi: 10.1007/s00787-017-0986-y
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: a historical perspective. Pediatrics. 2019 Oct;144(4). doi: 10.1542/peds.2019-1682
   Web of Science ®Google Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018 Apr;87:255–270. doi: 10.1016/j.neubiorev.2018.02.001
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Hagan JF Jr., Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4). doi: 10.1542/peds.2019-2528
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. [cited 2024 Mar 17]. Available from: https://www.nice.org.uk/guidance/ng87/chapter/Recommendations#medication
   Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727–738. doi: 10.1016/S2215-0366(18)30269-4
   PubMed Web of Science ®Google Scholar
• Fu D, Wu DD, Guo HL, et al. The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review. Front Psychiatry. 2021;12:780921. doi: 10.3389/fpsyt.2021.780921
   PubMed Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159–166. doi: 10.4088/PCC.v06n0403
   PubMedGoogle Scholar
• Highlights of Prescribing Information. Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, for oral use, CII. [cited 2024 Feb 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf
   Google Scholar
• Highlights of Prescribing Information. Concerta (methylphenidate HCl) extended-release tablets, CII. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s049lbl.pdf
   Google Scholar
• Schein J, Childress A, Adams J, et al. Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States – a retrospective claims analysis. BMC Psychiatry. 2022 Aug 18;22(1):555. doi: 10.1186/s12888-022-04188-4
   PubMed Web of Science ®Google Scholar
• Schein J, Childress A, Adams J, et al. Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study. Curr Med Res Opin. 2021 Nov;37(11):2007–2014. doi: 10.1080/03007995.2021.1968814
   PubMed Web of Science ®Google Scholar
• Brikell I, Yao H, Li L, et al. ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. Lancet Psychiatry. 2024 Jan;11(1):16–26. doi: 10.1016/S2215-0366(23)00332-2
   PubMedGoogle Scholar
• Biederman J, DiSalvo M, Green A, et al. Rates of switching stimulants in consecutively referred medication naive adults with ADHD. Acta Psychiatr Scand. 2021 Dec;144(6):626–634. doi: 10.1111/acps.13370
   PubMed Web of Science ®Google Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569. doi: 10.2147/NDT.S65721
   PubMed Web of Science ®Google Scholar
• Highlights of Prescribing Information. INTUNIV® (guanfacine) extended-release tablets, for oral use. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
   Google Scholar
• Highlights of Prescribing Information. KAPVAY® (clonidine hydrochloride) extended-release tablets, for oral use. [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf
   Google Scholar
• Highlights of prescribing information Strattera® (atomoxetine) capsules for oral use. [cited 2023 Sep 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411
   Google Scholar
• Highlights of Prescribing Information. QelbreeTM (viloxazine extended-release capsules). [cited 2024 Feb 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf
   Google Scholar
• US Food & Drug Administration NDA 211964/S-003 Supplement Approval. [cited 2024 Feb 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211964Orig1s003ltr.pdf
   Google Scholar
• Childress A, Mattingly G, Wright C, et al. Assessing patient perceptions in the care of adults with ADHD. Nevada Psychiatric Association Annual National Psychopharmacology Update; Las Vegas, NV: 2024 Feb 15–17.
   Google Scholar
• Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr. 2009 Sep;48(7):723–733. doi: 10.1177/0009922809335321
   PubMed Web of Science ®Google Scholar
• Wilens TE, McBurnett K, Turnbow J, et al. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD. J Atten Disord. 2017 Jan;21(2):110–119. doi: 10.1177/1087054713500144
   PubMed Web of Science ®Google Scholar
• Childress A, Hayman K, Asubonteng K, et al. Viloxazine ER (Qelbree®) administered with psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder: topline results of a phase IV safety trial. Psych Congress. 2023 Sep 6–10; Nashville, TN.
   Google Scholar
• Upadhyaya HP, Desaiah D, Schuh KJ, et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacol (Berl). 2013 Mar;226(2):189–200. doi: 10.1007/s00213-013-2986-z
   PubMed Web of Science ®Google Scholar
• Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980 Jan;12(1):155–161. doi: 10.1016/0091-3057(80)90430-X
   PubMed Web of Science ®Google Scholar
• Fox HC, Seo D, Tuit K, et al. Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol. 2012 Jul;26(7):958–972. doi: 10.1177/0269881111430746
   PubMed Web of Science ®Google Scholar
• Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014 Sep;126(5):64–81. doi: 10.3810/pgm.2014.09.2801
   PubMed Web of Science ®Google Scholar
• Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2016;12:27–39. doi: 10.2147/TCRM.S59270
   PubMed Web of Science ®Google Scholar
• Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242–251. doi: 10.1097/01.chi.0000246056.83791.b6
   PubMed Web of Science ®Google Scholar
• Smith RL, Molden E, Bernard JP. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data. Br J Clin Pharmacol. 2023 Jul;89(7):2246–2253. doi: 10.1111/bcp.15706
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Sutton VK, Weiss MD, et al. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the integrated data exploratory analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):511–518. doi: 10.1097/CHI.0b013e31819c55b2
   PubMed Web of Science ®Google Scholar
• Bushe C, Sobanski E, Coghill D, et al. Post Hoc analysis of potential predictors of response to atomoxetine for the treatment of adults with attention-deficit/hyperactivity disorder using an integrated database. CNS Drugs. 2016 Apr;30(4):317–334. doi: 10.1007/s40263-016-0323-x
   PubMed Web of Science ®Google Scholar
• Childress AC, Kando JC, King TR, et al. Early-onset efficacy and safety pilot study of amphetamine extended-release oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2–8. doi: 10.1089/cap.2018.0078
   PubMed Web of Science ®Google Scholar
• Kollins SH, Braeckman R, Guenther S, et al. A randomized, controlled laboratory classroom study of serdexmethylphenidate and D-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021 Nov;31(9):597–609. doi: 10.1089/cap.2021.0077
   PubMed Web of Science ®Google Scholar
• Upadhyaya H, Ramos-Quiroga JA, Adler LA, et al. Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study. Eur J Psychiat. 2013;27(3):185–205. doi: 10.4321/S0213-61632013000300004
   Web of Science ®Google Scholar
• Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007 Oct;17(5):689–700. doi: 10.1089/cap.2006.0100
   PubMed Web of Science ®Google Scholar
• Biederman J, DiSalvo M, Green A, et al. Growth trajectories in stimulant-treated children ages 6 to 12: an electronic medical record analysis. J Dev Behav Pediatr. 2023 Feb 1;44(2):e80–e87. doi: 10.1097/DBP.0000000000001156
   PubMed Web of Science ®Google Scholar
• Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):493–499. doi: 10.1089/cap.2008.0126
   PubMed Web of Science ®Google Scholar
• Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I Effectiveness. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485–492. doi: 10.1089/cap.2008.0125
   PubMed Web of Science ®Google Scholar
• Quintana H, Cherlin EA, Duesenberg DA, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder – a preliminary tolerability and efficacy study. Clin Ther. 2007 Jun;29(6):1168–1177. doi: 10.1016/j.clinthera.2007.06.017
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species. Neurobiol Learn Mem. 2020 Dec;176:107327. doi: 10.1016/j.nlm.2020.107327
   PubMed Web of Science ®Google Scholar
• Department of health and human services food and drug administration silver spring, MD 20993 NDA 22037 NDA APPROVAL. [cited 2024 Mar 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022037s000ltr.pdf
   Google Scholar
• Product monograph intuniv XR® guanfacine hydrochloride extended-release tablets. [cited 2024 Mar 4]. Available from: https://pdf.hres.ca/dpd_pm/00042213.PDF
   Google Scholar
• Shire receives European Commission’s approval for Intuniv. [cited 2024 Mar 4]. Available from: https://www.reuters.com/article/idUSFWN11O015/
   Google Scholar
• Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science. 1985 Dec 13;230(4731):1273–1276. doi: 10.1126/science.2999977
   PubMed Web of Science ®Google Scholar
• Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 Jan;34(1):50–54. doi: 10.1097/00004583-199501000-00013
   PubMed Web of Science ®Google Scholar
• Description Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with α2-adrenoceptor agonist properties in tablet form for oral administration. [cited 2024 Mar 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf
   Google Scholar
• Childress A, Hoo-Cardiel A, Lang P. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother. 2020 Mar;21(4):417–426. doi: 10.1080/14656566.2019.1706480
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155–165. doi: 10.1097/CHI.0b013e318191769e
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008 Jan;121(1):e73–84. doi: 10.1542/peds.2006-3695
   PubMed Web of Science ®Google Scholar
• Wilens TE, Robertson B, Sikirica V, et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916–25 e2. doi: 10.1016/j.jaac.2015.08.016
   PubMed Web of Science ®Google Scholar
• Huss M, Dirks B, Gu J, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1283–1294. doi: 10.1007/s00787-018-1113-4
   PubMed Web of Science ®Google Scholar
• Iwanami A, Saito K, Fujiwara M, et al. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2020 Apr 14;81(3). doi: 10.4088/JCP.19m12979
   PubMed Web of Science ®Google Scholar
• Iwanami A, Saito K, Fujiwara M, et al. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study. BMC Psychiatry. 2020 Oct 2;20(1):485. doi: 10.1186/s12888-020-02867-8
   PubMed Web of Science ®Google Scholar
• Department of health and human services food and drug administration silver spring MD 20993 NDA 022331 NDA Approval. [cited 2024 Mar 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022331s000ltr.pdf
   Google Scholar
• Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999 Dec;38(12):1551–1559. doi: 10.1097/00004583-199912000-00017
   PubMed Web of Science ®Google Scholar
• Catapres-TTS (clonidine transdermal system). [cited 2024 Mar 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018891Orig1s032correctedlbl.pdf
   Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171–179. doi: 10.1016/j.jaac.2010.11.005
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011 Jun;127(6):e1406–13. doi: 10.1542/peds.2010-1260
   PubMed Web of Science ®Google Scholar
• Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. doi: 10.2147/JEP.S256586
   PubMedGoogle Scholar
• Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021 Jun;35(6):643–653. doi: 10.1007/s40263-021-00825-w
   PubMed Web of Science ®Google Scholar
• Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. 2021 Feb;41(2):149–159. doi: 10.1007/s40261-020-00992-6
   PubMed Web of Science ®Google Scholar
• Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021 Mar 1;41(2):155–162. doi: 10.1097/JCP.0000000000001361
   PubMed Web of Science ®Google Scholar
• Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020 Jan;24(2):348–358. doi: 10.1177/1087054719836159
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021 Mar 16;51(2):43–64. doi: 10.1016/j.clinthera.2021.01.027
   PubMedGoogle Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021 Jul 1;41(4):370–380. doi: 10.1097/JCP.0000000000001404
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021
   PubMed Web of Science ®Google Scholar
• Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 Apr;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027
   PubMed Web of Science ®Google Scholar
• Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022 Aug;36(8):897–915. doi: 10.1007/s40263-022-00938-w
   PubMed Web of Science ®Google Scholar
• Findling R, Fry N, Hull JT, et al. Viloxazine extended-release capsules in children and adolescents with attention-deficit/hyperactivity disorder: final results of a long-term, phase 3 open-label extension study. In: American Academy of Child and Adolescent Psychiatry 70th Annual Meeting; New York, NY: 2023 Oct 23–28.
   Google Scholar
• Childress A, C AJ, A LA, et al. Qelbree® (viloxazine extended-release capsules): Final results of the long-term, phase 3, open-label extension trial in adults with ADHD. Am Soc Clin Psychopharmacol. 2023 May 30 – June 2; Miami Beach, FL.
   Google Scholar
• Nasser A, Hull JT, Tesfaye L, et al. Assessment of pediatric weight and height trajectories during long-term viloxazine ER (Qelbree®) treatment in an open-label extension safety trial. In: Neuroscience education institute (NEI) congress. Colorado Srings CO; 2022 Nov 3–6.
   Google Scholar
• C A, Hayman K, Asubonteng K, et al. Viloxazine ER (Qelbree®) administered with psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder: results of a phase IV safety trial. Psych Congress. 2023 Sep 6–10; Nashville, TN.
   Google Scholar
• Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022 Sep 1;42(5):429–439. doi: 10.1097/JCP.0000000000001575
   PubMed Web of Science ®Google Scholar
• Ward C, Jin N, Skubiak T, et al. Efficacy and safety of once-daily extended-release centanafadine for the treatment of attention-deficit/hyperactivity disorder in adolescents aged 13–17 years. In: American Professional Society of ADHD and Related Disorders Annual Meeting; Orlando, FL: 2024 Jan 17–21.
   Google Scholar
• Ward C, Jin N, Skubiak T, et al. Efficacy and safety of once-daily extended-release centanafadine for the treatment of attention-deficit/hyperactivity disorder in children aged 6–12 years. American Professional Society of ADHD and Related Disorders Annual Meeting: Orlando, FL; 2024 Jan 17–21.
   Google Scholar
• ClinicalTrials.gov. A study to access the efficacy and safety of solriamfetol in subjects with ADHD (FOCUS). [cited 2024 Mar 10]. Available from: https://clinicaltrials.gov/study/NCT05972044?cond=adhd&term=solriamfetol&rank=1
   Google Scholar
• Clinicaltrials.gov. Study to evaluate NRCT-101SR in adult attention deficit hyperactivity disorder (ADHD). [cited 2024 Mar 10]. Available from: https://www.clinicaltrials.gov/study/NCT05683249
   Google Scholar
• Otsuka Pharmaceutical Co. Ltd. Otsuka Pharmaceutical to Acquire Neurovance, Inc. Acquisition of clinical-stage company in ADHD widens Otsuka’s presence in mental health. [cited 2024 Mar 10]. Available from: https://www.otsuka.co.jp/en/company/newsreleases/2017/20170303_1.html
   Google Scholar
• Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. The Synapse. 2012 Jun;66(6):522–532. doi: 10.1002/syn.21538
   PubMed Web of Science ®Google Scholar
• Heal D, Rowley HL, Smith S, et al. Evaluation of the discriminative and reinforcing potential of centanafadine and reference comparator ADHD drugs by drug-discrimination and intravenous self-administration testing in rats. Neuropsychopharmacol. 2020 Dec;45:278–382.
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal T, Hobart M, et al. Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies. Neuropsychiatr Dis Treat. 2020;16:1411–1426. doi: 10.2147/NDT.S242084
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information Sunosi® (solriamfetol) tablets, for oral use, CIV. [cited 2024 Mar 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf
   Google Scholar
• About Sunosi. [cited 2024 Mar 15]. Available from: https://www.sunosi.com/about-sunosi
   Google Scholar
• Surman CBH, Walsh DM, Horick N, et al. Solriamfetol for attention-deficit/hyperactivity disorder in adults: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2023 Oct 9;84(6). doi: 10.4088/JCP.23m14934
   PubMed Web of Science ®Google Scholar
• Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165–177. doi: 10.1016/j.neuron.2009.12.026
   PubMed Web of Science ®Google Scholar
• Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol Brain. 2014 Sep 13;7(1):65. doi: 10.1186/s13041-014-0065-y
   PubMedGoogle Scholar
• Liu G, Weinger JG, Lu ZL, et al. Efficacy and safety of MMFS-01, a Synapse Density Enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2016;49(4):971–990. doi: 10.3233/JAD-150538
   PubMed Web of Science ®Google Scholar
• Surman C, Vaudreuil C, Boland H, et al. L-Threonic acid magnesium salt supplementation in ADHD: an open-label Pilot study. J Diet Suppl. 2021;18(2):119–131. doi: 10.1080/19390211.2020.1731044
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Treatment with cannabis oil containing CBD, THC, CBDV or CBG vs. Placebo of persons with ADHD. [cited 2024 Mar 16]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05219370
   Google Scholar
• Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacol. 2015 Nov;40(12):2745–2752. doi: 10.1038/npp.2015.124
   PubMed Web of Science ®Google Scholar
• Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):80–89. doi: 10.1089/cap.2018.0083
   PubMed Web of Science ®Google Scholar
• Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and safety of dasotraline in children with ADHD: A laboratory classroom study. J Atten Disord. 2020 Jan;24(2):192–204. doi: 10.1177/1087054719864644
   PubMed Web of Science ®Google Scholar
• Wigal S, Tsai J, Bates JA, et al. A randomized, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with ADHD. J Atten Disord. 2022 Aug;26(10):1357–1368. doi: 10.1177/10870547211073477
   PubMed Web of Science ®Google Scholar
• Sunovion Discontinues Dasotraline Program. [cited 2024 Mar 16]. Available from: https://news.sunovion.com/press-releases/press-releases-details/2020/Sunovion-Discontinues-Dasotraline-Program/default.aspx
   Google Scholar
• Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med. 2013 Jul;125(4):181–190. doi: 10.3810/pgm.2013.07.2689
   PubMed Web of Science ®Google Scholar
• Practice Update Metadoxine Missed Primary Endpoint in Phase III ADHD Trial. [cited 2024 Mar 16]. Available from: https://www.practiceupdate.com/content/metadoxine-missed-primary-endpoint-in-phase-iii-adhd-trial/19141
   Google Scholar
• Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol. 2019 Apr;33(4):511–521. doi: 10.1177/0269881119832538
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. The safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder. [cited 2024 Mar 16]. Available from: https://clinicaltrials.gov/study/NCT03324581
   Google Scholar
• Adis Insight. Drug Profile OPC-64005. [cited 2024 Mar 16]. Available from: https://adisinsight.springer.com/drugs/800045471
   Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008 Winter;14(4):295–314. doi: 10.1111/j.1755-5949.2008.00059.x
   PubMed Web of Science ®Google Scholar
• Businesswire. MindMed announces business update and anticipated milestones for. 2024 [cited 2024 Mar 16]. Available from: https://www.businesswire.com/news/home/20240108449557/en/MindMed-Announces-Business-Update-and-Anticipated-Milestones-for-2024
   Google Scholar
• Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013 Dec;27(12):1081–1092. doi: 10.1007/s40263-013-0104-8
   PubMed Web of Science ®Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005 Aug;9(1):275–289. doi: 10.1177/1087054705281121
   PubMedGoogle Scholar
• Childress AC, Sallee FR. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012 Mar;48(3):207–217. doi: 10.1358/dot.2012.48.3.1750904
   PubMed Web of Science ®Google Scholar
• Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023 Jul;37(7):655–660. doi: 10.1007/s40263-023-01023-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to access the efficacy and safety of solriamfetol in subjects with ADHD (FOCUS). [cited 2024 Mar 17]. Available from: https://clinicaltrials.gov/study/NCT05972044?cond=ADHD&term=solriamfetol&rank=1
   Google Scholar
• ClinicalTrials.gov. Study to evaluate NRCT-101SR in adult attention deficit hyperactivity disorder (ADHD). [cited 2024 Mar 17]. Available from: https://clinicaltrials.gov/study/NCT05683249?cond=ADHD&term=neurocentria&rank=1
   Google Scholar
• Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425–441. doi: 10.1007/s00787-021-01899-z
   PubMed Web of Science ®Google Scholar
• Canadian ADHD Practice Guidelines. [cited 2023 Jul 1]. Available from: https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
   Google Scholar
• Australian Evidence-Based Clinical Practice Guideline For Attention Deficit Hyperactivity Disorder. [cited 2023 Jul 1]. Available from: https://adhdguideline.aadpa.com.au/download/
   Google Scholar
• Stein MA, Zulauf-McCurdy C, DelRosso LM. Attention deficit hyperactivity disorder medications and sleep. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):499–514. doi: 10.1016/j.chc.2022.03.006
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial of centanafadine long-term safety in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). [cited 2024 Mar 17]. Available from: https://clinicaltrials.gov/study/NCT05279313?cond=ADHD&term=centanafadine%20open&rank=1
   Google Scholar
• Buitelaar J, Bolte S, Brandeis D, et al. Toward precision medicine in ADHD. Front Behav Neurosci. 2022;16:900981. doi: 10.3389/fnbeh.2022.900981
   PubMed Web of Science ®Google Scholar
• Stage C, Jurgens G, Guski LS, et al. The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers. Basic Clin Pharmacol Toxicol. 2017 Dec;121(6):487–492. doi: 10.1111/bcpt.12835
   PubMed Web of Science ®Google Scholar
• Yu G, Li GF, Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314–326. doi: 10.1089/cap.2015.0137
   PubMed Web of Science ®Google Scholar